Embecta Corp

Embecta Corp. engages in manufacturing and distributing medical devices used in the treatment of diabetes. It delivers insulin for diabetic patients to improve their lives. The company is headquartered in Parsippany, NJ.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Embecta Corp reports robust Q2 earnings, eyes growth opportunities

Embecta Corp's Q2 2023 earnings call highlighted strong financial performance, strategic priorities for 2023, and updated guidance. The company is focused on improving diabetes care, revenue diversification, and addressing challenges like the China manufacturing shutdown. Opportunities exist in partnerships, addressing needle reuse, and strategic M&A.

Embecta Corp reports Q3 revenue growth amidst margin challenges

EMBC's Q3 performance showed revenue growth and adjusted net income, despite challenges in U.S. revenue and margin decline
The company's strengths lie in successful product launches, international revenue growth, and future pipeline optimism
Challenges include revenue decline in the U.S., margin pressures, and monitoring competitive threats
Opportunities include demerger process initiation, focus on open-loop system, and improved guidance for 2023

Embecta Corp exceeds revenue expectations in Q4 2023 earnings call

Embecta Corp's Q4 2023 earnings call highlighted revenue growth, strong gross margins, and strategic priorities for fiscal 2024. Despite challenges in TSA expenses and revenue decline projections for 2024, the company remains focused on growth opportunities. Management's commitment to maintaining a 30% adjusted EBITDA margin showcases confidence in the base business.

Embecta Corp surpasses Q1 revenue expectations, raises EPS guidance

Embecta Corp's Q1 performance exceeded expectations, showcasing resilience in its core business and progress in strategic initiatives. While facing challenges related to the ERP transition, the company is well-positioned to leverage opportunities for growth and profitability.

Embecta Corp (EMBC) reports strong Q2 earnings and eyes market expansion

Embecta Corp (EMBC) delivered a robust Q2 performance, exceeding revenue expectations and raising adjusted earnings per share guidance.
The company showcased operational efficiency through successful initiatives like ERP system implementation and distribution network expansion.
While facing challenges in revenue outlook and cash flow management, Embecta remains focused on innovation and market resilience for sustained growth.

Embecta Corp reports Q3 revenue decline but affirms growth outlook

Embecta Corp's Q3 performance reflected revenue decline but strong strategic progress.
The company faces challenges in managing separation costs and addressing revenue decreases.
Opportunities lie in new product introductions, FDA applications, and market development initiatives.

Embecta Corp surpasses 2024 expectations, announces restructuring plan

Embecta Corp's Q4 2024 performance exceeded expectations with revenue growth and EBITDA margin
The company announced a restructuring plan to discontinue the insulin patch pump program for cost savings
Future strategic priorities aim to strengthen core business and expand product portfolio

Embecta Corp exceeds revenue expectations, focuses on debt reduction

Embecta Corp's Q1 2025 performance showed resilience with revenue exceeding expectations and disciplined debt management.
The company's strengths lie in its brand transition progress, healthy cash balance, and improved margin guidance.
Challenges include revenue decline, aggressive debt reduction targets, and operational optimizations, while opportunities exist in M&A and margin expansion.

Embecta Corp surpasses Q2 revenue expectations, eyes growth opportunities

Embecta Corp's Q2 performance exceeded expectations, driven by strategic initiatives and strong partnerships. While facing challenges like revenue adjustments, the company is poised for growth through product expansion and financial flexibility. Investors can look forward to gaining deeper insights into Embecta's future plans at the upcoming Analyst and Investor Day.

Embecta Corp exceeds Q3 revenue expectations, eyes international expansion

Embecta Corp's Q3 2025 earnings call showcased strong revenue performance, international growth, and financial discipline. The company's focus on debt reduction, financial flexibility, and product portfolio expansion bodes well for future prospects. While challenges like managing growth rates and market impacts exist, strategic adjustments can turn them into opportunities for growth.

Embecta Corp reports Q4 revenue decline but boosts profitability

Embecta Corp's Q4 2025 performance reflects revenue decline but improved profitability metrics. Key strengths include successful strategic initiatives and improved operating margins. Challenges lie in revenue decline, lower gross profit, and potential revenue impact of partnerships. Opportunities include leveraging foreign currency tailwinds and exploring investment avenues for growth.

Embecta Corp reports $261M revenue in Q1 2026 earnings call

Embecta Corp's Q1 2026 earnings call highlighted revenue performance, strategic roadmap phases, and financial metrics. Despite U.S. pricing challenges, the company remains focused on growth opportunities in international markets and new product developments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.